Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

1.

Aromatase inhibitors and bone health in women with breast cancer.

Chien AJ, Goss PE.

J Clin Oncol. 2006 Nov 20;24(33):5305-12. Review. No abstract available.

PMID:
17114665
[PubMed - indexed for MEDLINE]
2.

Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.

Freedman OC, Verma S, Clemons MJ.

Breast Cancer Res Treat. 2006 Oct;99(3):241-7. Epub 2006 Jun 3. Review.

PMID:
16752075
[PubMed - indexed for MEDLINE]
3.

Women and bone health: maximizing the benefits of aromatase inhibitor therapy.

Tang SC.

Oncology. 2010;79(1-2):13-26. doi: 10.1159/000314997. Epub 2010 Nov 3. Review.

PMID:
21051913
[PubMed - indexed for MEDLINE]
4.

Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE.

Cancer Treat Rev. 2008;34 Suppl 1:S3-18. doi: 10.1016/j.ctrv.2008.03.007. Epub 2008 Jun 2.

PMID:
18515009
[PubMed - indexed for MEDLINE]
5.

[Effect of aromatase inhibitors on bone metabolism].

Folkestad L, Bjerregaard JK, Bjarnason NH, Brixen KT.

Ugeskr Laeger. 2007 May 7;169(19):1774-9. Review. Danish.

PMID:
17537350
[PubMed - indexed for MEDLINE]
6.

[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].

van Nes JG, Seynaeve C, van de Velde CJ, Nortier JW.

Ned Tijdschr Geneeskd. 2006 Dec 30;150(52):2863-9. Review. Dutch.

PMID:
17319217
[PubMed - indexed for MEDLINE]
7.

Current developments in hormonal therapy of breast cancer.

Buzdar AU.

Clin Breast Cancer. 2004 Sep;5 Suppl 1:S4-5. Review. No abstract available.

PMID:
15347432
[PubMed - indexed for MEDLINE]
8.

Aromatase inhibitors and bone health.

Bundred NJ.

Curr Opin Obstet Gynecol. 2009 Feb;21(1):60-7. doi: 10.1097/GCO.0b013e32831da80e. Review.

PMID:
19125005
[PubMed - indexed for MEDLINE]
9.

Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.

Macaskill EJ, Renshaw L, Dixon JM.

Oncologist. 2006 Nov-Dec;11(10):1081-8. Review.

PMID:
17110627
[PubMed - indexed for MEDLINE]
Free Article
10.

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Carpenter R.

Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Review.

PMID:
18296017
[PubMed - indexed for MEDLINE]
11.

Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

Jahanzeb M.

Clin Ther. 2007 Aug;29(8):1535-47. Review.

PMID:
17919537
[PubMed - indexed for MEDLINE]
12.

[Advancement in endocrine therapy for breast cancer].

Yang MT, Lian ZQ.

Ai Zheng. 2007 Apr;26(4):440-4. Review. Chinese.

PMID:
17430670
[PubMed - indexed for MEDLINE]
13.

Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors.

Brufsky AM.

Curr Oncol Rep. 2008 Jan;10(1):18-26. Review.

PMID:
18366957
[PubMed - indexed for MEDLINE]
14.

Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.

Sanford M, Plosker GL.

Drugs. 2008;68(9):1319-40. Review.

PMID:
18547136
[PubMed - indexed for MEDLINE]
15.

Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.

Conte P, Frassoldati A.

Breast J. 2007 Jan-Feb;13(1):28-35. Review.

PMID:
17214790
[PubMed - indexed for MEDLINE]
16.

The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.

Monnier AM.

Expert Rev Anticancer Ther. 2007 May;7(5):627-34. Review.

PMID:
17492927
[PubMed - indexed for MEDLINE]
17.

The effect of aromatase inhibitors on bone metabolism.

Folkestad L, Bjarnason NH, Bjerregaard JK, Brixen K.

Basic Clin Pharmacol Toxicol. 2009 Jan;104(1):3-10. doi: 10.1111/j.1742-7843.2008.00337.x. Review.

PMID:
19152547
[PubMed - indexed for MEDLINE]
18.

Cancer treatment-induced bone loss in breast and prostate cancer.

Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI.

J Clin Oncol. 2008 Nov 20;26(33):5465-76. doi: 10.1200/JCO.2008.18.4184. Epub 2008 Oct 27. Review.

PMID:
18955443
[PubMed - indexed for MEDLINE]
19.

Targeting breast cancer with hormonal treatment options.

Mellington TE, Fields MM.

Nurse Pract. 2008 May;33(5):17-22; quiz 22-3. doi: 10.1097/01.NPR.0000317483.12297.0a. Review. No abstract available.

PMID:
18458623
[PubMed - indexed for MEDLINE]
20.

[Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].

Xiu Bing-He; Consensus Expert Group For Prevention Diagnosis And Treatment Of Bone Loss And Osteoporosis In Postmenopausal Breast Cancer Patients After Aromatase Inhibitor Therapy.

Zhonghua Zhong Liu Za Zhi. 2013 Nov;35(11):876-9. Chinese. No abstract available.

PMID:
24447490
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk